查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1815300

髓系细胞标靶治疗市场报告：2031 年趋势、预测与竞争分析

Myeloid Cell Targeting Therapeutic Market Report: Trends, Forecast and Competitive Analysis to 2031
出版日期: | 出版商: Lucintel | 英文 150 Pages | 商品交期: 3个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

全球髓系细胞标靶治疗市场前景光明，肿瘤学和罕见疾病市场蕴藏着巨大机会。预计2025年至2031年，全球髓系细胞标靶治疗市场的复合年增长率将达33.1%。医疗保健支出的增加和研发投入的增加是推动该市场成长的关键因素。

  • Lucintel 预测，静脉注射将在预测期内继续成为最大的细分市场，因为它是最有效的方法。
  • 从应用角度来看，由于针对髓系细胞的治疗需求很大，因此预计肿瘤疾病将出现高速成长。
  • 按地区划分，预计北美在预测期内将经历最高的成长。

骨髓细胞标靶治疗市场的新趋势

随着髓系细胞标靶治疗市场的发展，多种趋势正在塑造其未来，推动创新并扩展其应用。这些趋势受到分子生物学的进步、对免疫调节的日益深入理解以及对标靶治疗（尤其是在肿瘤领域）日益增长的需求的影响。以下五大关键趋势正在重塑髓系细胞标靶治疗的模式。

  • 免疫肿瘤学整合：髓系标靶治疗正被整合到癌症免疫疗法中，尤其用于解决免疫逃脱机制。髓系抑制细胞 (MDSC) 在塑造免疫抑制性肿瘤微环境中发挥关键作用，阻碍了常规治疗方法的疗效。靶向 MDSC 和巨噬细胞正成为增强查核点抑制剂、CAR-T 疗法和单株抗体疗效的有前景的策略。这种整合正在加速临床试验，并拓展旨在重编程髓系细胞以支持抗肿瘤免疫的免疫疗法研发管线。
  • 迈向个人化医疗：个人化医疗正成为髓系细胞标靶治疗市场的一大趋势。透过利用基因和免疫分析，研究人员能够识别影响疾病进展的特定髓系细胞亚型，尤其是在癌症和自体免疫疾病中。针对这些特定细胞群的客製化治疗方法已改善了临床疗效并减少了副作用。随着基因组学和免疫学的进步，可以更好地对患者进行分层，从而优化治疗效果和安全性，预计这一趋势将持续下去。
  • 联合治疗：髓系细胞标靶治疗与其他疗法（例如化疗、放射线治疗和生技药品）的联合应用日益受到重视。这一趋势利用免疫调节与常规治疗相结合的协同效应来克服抗药性机制。例如，巨噬细胞重编程药物与查核点抑制剂的联合应用有望增强肿瘤反应。此策略旨在透过解决免疫抑制的多面性来应对肿瘤微环境的复杂性，从而提高整体治疗效果并降低復发率。
  • 自体免疫疾病疗法的扩展：虽然癌症传统上一直是髓系细胞标靶疗法的主要关注点，但目前正逐渐转向自体免疫疾病。髓系细胞，尤其是树突细胞和巨噬细胞，在类风湿性关节炎和多发性硬化症等自体免疫疾病的发展中起着关键作用。靶向这些细胞以恢復免疫耐受性作为一种新的治疗方法正日益受到关注。这一趋势正在拓宽市场基础，目前除了癌症之外，髓系标靶药物也正在被开发用于治疗发炎性疾病。
  • 监管发展与加速核准：包括美国、中国和欧盟在内的主要地区的监管机构正在对髓系细胞标靶治疗采取更灵活、更快捷的核准途径。这一趋势源自于肿瘤和慢性病领域对创新疗法日益增长的需求。例如，美国食品药物管理局 (FDA) 的突破性疗法认定和中国的有条件核准程序正在促进这些疗法的更快可及性。监管机构对新型免疫疗法早期临床试验和核准的支持正在加速市场成长，使骨髓标靶药物更快地惠及病患。

髓系细胞标靶治疗的这些新趋势正在彻底改变治疗模式。由于与癌症免疫疗法的整合、个人化治疗方案的采用、与其他治疗方法的联合应用、向自体免疫疾病领域的扩展以及监管方面的进步，该市场有望实现显着增长。这些趋势不仅推动了创新，也拓展了治疗范围，为多种疾病的治疗提供了新的途径。

髓系标靶治疗市场的最新趋势

髓系标靶治疗领域的最新进展取得了显着进展，尤其是在免疫治疗领域。目前正在研究操纵髓系细胞（包括巨噬细胞、树突状细胞和骨髓间质干细胞）的新方法，以治疗癌症和自体免疫疾病。这些进展代表着治疗策略的重大转变，多项进展正在影响药物研发、临床试验和市场成长。髓系标靶治疗市场的关键进展包括：

  • MDSC调控在癌症治疗中的突破：针对髓系抑制细胞 (MDSC) 的癌症免疫疗法取得了突破性进展。这些细胞有助于肿瘤诱导的免疫抑制，并阻止有效的抗癌免疫反应。最近的进展促成了新型药物和免疫调节剂的发现，它们可以重编程 MDSC，增强人体对肿瘤的免疫反应。早期临床试验已显示出良好的结果，尤其是与免疫查核点抑制剂合併使用，这使得 MDSC 调控成为下一代癌症治疗的关键组成部分。
  • 标靶巨噬细胞极化研究进展：巨噬细胞兼具促发炎和抗发炎特性，靶向巨噬细胞极化已显示出在癌症和慢性发炎疾病中的治疗潜力。近期研究重点在于将巨噬细胞从免疫抑制性M2表型重编程为肿瘤抑制性M1表型。研究人员正在开发能够改变巨噬细胞极化的小分子和生物药品，以提供新的治疗方法。该策略目前正在临床试验中，早期结果显示肿瘤消退，免疫系统活化增强。
  • 自体免疫疾病的新型临床试验：髓系细胞的关注正从肿瘤学扩展到自体免疫疾病。最近的临床试验正在研究针对树突状细胞和巨噬细胞的治疗方法，以调节免疫反应并恢復免疫耐受性。这些治疗方法旨在治疗免疫失调起关键作用的疾病，例如类风湿性关节炎、红斑性狼疮和多发性硬化症。虽然该领域的临床开发仍处于早期阶段，但它有望改善自体免疫疾病患者的治疗效果。
  • 生物技术与学术界的合作：生物技术公司与学术机构之间的合作日益增多，旨在推进骨髓标靶治疗方法的研究。此类伙伴关係对于将实验室发现转化为临床应用至关重要。值得关注的合作正在加速开髮用于患者选择的新型生物标记物，并提高髓系细胞标靶治疗方法的疗效。这些合作为下一代免疫疗法铺平了道路，并扩大了骨髓标靶治疗的应用范围。
  • 免疫肿瘤学投资不断增加：来自私营和公共部门的不断增加的投资正在刺激髓系细胞靶向治疗市场的创新。免疫肿瘤学，尤其是针对肿瘤微环境的治疗方法，已成为生技公司关注的重点。大量资金正投入巨噬细胞、树突状细胞和骨髓间质干细胞（MDSC）的研究中，以克服肿瘤的免疫抗药性。这种投资的增加正在加速新型髓系标靶治疗方法的研发，从而带来更具竞争力和活力的市场。

髓系细胞标靶治疗市场的最新进展使其成为一个快速发展且充满活力的细分市场。从MDSC调控领域的突破到针对自体免疫疾病的全新临床试验，这些进展正在重塑治疗模式。不断增加的投资、学术合作以及在自体免疫疾病和癌症领域的拓展，正在推动该市场的成长，并有望彻底改变各种疾病的治疗方式。

目录

第一章执行摘要

第二章 市场概况

  • 背景和分类
  • 供应链

第三章：市场趋势及预测分析

  • 宏观经济趋势与预测
  • 产业驱动力与挑战
  • PESTLE分析
  • 专利分析
  • 法规环境

4. 全球髓系细胞标靶治疗市场（按类型）

  • 概述
  • 按类型进行吸引力分析
  • 静脉输液：趋势与预测（2019-2031）
  • 口语：趋势与预测（2019-2031）
  • 其他：趋势与预测（2019-2031）

5. 全球髓系细胞标靶治疗市场（依应用）

  • 概述
  • 按用途进行吸引力分析
  • 肿瘤学：趋势与预测（2019-2031）
  • 罕见疾病：趋势与预测（2019-2031）
  • 其他：趋势与预测（2019-2031）

第六章 区域分析

  • 概述
  • 骨髓细胞标靶治疗市场（按地区）

7. 北美髓系细胞标靶治疗市场

  • 概述
  • 美国髓系细胞标靶治疗市场
  • 墨西哥的髓系细胞标靶治疗市场
  • 加拿大髓系细胞标靶治疗市场

8. 欧洲骨髓细胞标靶治疗市场

  • 概述
  • 德国髓系细胞标靶治疗市场
  • 法国髓系细胞标靶治疗市场
  • 西班牙髓系细胞标靶治疗市场
  • 义大利髓系细胞标靶治疗市场
  • 英国髓系细胞标靶治疗市场

9. 亚太地区髓系细胞标靶治疗市场

  • 概述
  • 日本骨髓细胞标靶治疗市场
  • 印度髓系细胞标靶治疗市场
  • 中国骨髓细胞标靶治疗市场
  • 韩国骨髓细胞标靶治疗市场
  • 印尼骨髓细胞标靶治疗市场

10. 其他地区髓系细胞标靶治疗市场

  • 概述
  • 中东髓系细胞标靶治疗市场
  • 南美洲髓系细胞标靶治疗市场
  • 非洲髓系细胞标靶治疗市场

第11章 竞争分析

  • 产品系列分析
  • 营运整合
  • 波特五力分析
    • 竞争对手之间的竞争
    • 买方的议价能力
    • 供应商的议价能力
    • 替代品的威胁
    • 新进入者的威胁
  • 市占率分析

第十二章：机会与策略分析

  • 价值链分析
  • 成长机会分析
    • 按类型分類的成长机会
    • 按应用分類的成长机会
  • 全球髓系细胞标靶治疗市场的新趋势
  • 战略分析
    • 新产品开发
    • 认证和许可
    • 合併、收购、协议、合作和合资企业

第十三章 价值链主要企业的公司简介

  • 竞争分析
  • ChemoCentryx
  • Daiichi Sankyo
  • Gilead Sciences
  • Janssen BIoTech
  • Roche
  • Pfizer
  • GlaxoSmithKline
  • Macrophage Pharma
  • Enlivex
  • Immune-Onc Therapeutics

第十四章 附录

  • 图表目录
  • 表格一览
  • 调查方法
  • 免责声明
  • 版权
  • 简称和技术单位
  • 关于我们
  • 联络处

The future of the global myeloid cell targeting therapeutic market looks promising with opportunities in the oncological disorders and rare disorders markets. The global myeloid cell targeting therapeutic market is expected to grow with a CAGR of 33.1% from 2025 to 2031. The major drivers for this market are the increasing healthcare expenditure and the increased investment in R&D.

  • Lucintel forecasts that, within the type category, intravenous injection will remain larger segment over the forecast period due to intravenous injection, as it is the most efficient and effective method.
  • Within the application category, oncological disorders is expected to witness the higher growth due to the significant demand for myeloid cell-targeted therapies.
  • In terms of region, North America is expected to witness the highest growth over the forecast period.

Emerging Trends in the Myeloid Cell Targeting Therapeutic Market

As the myeloid cell targeting therapeutic market evolves, several trends are shaping its future, driving innovation, and expanding its applications. These trends are influenced by advancements in molecular biology, increased understanding of immune modulation, and growing demand for targeted therapies, particularly in oncology. Below are five key trends that are transforming the landscape of myeloid cell targeting.

  • Immuno-oncology Integration: Myeloid cell targeted therapies are increasingly being integrated into cancer immunotherapy, particularly to address immune evasion mechanisms. Myeloid-derived suppressor cells (MDSCs) play a key role in creating an immunosuppressive tumor microenvironment, which hampers the effectiveness of conventional therapies. Targeting MDSCs and macrophages is becoming a promising strategy to enhance the efficacy of checkpoint inhibitors, CAR-T therapies, and monoclonal antibodies in oncology. This integration has led to accelerated clinical trials and a growing pipeline of immunotherapies aimed at reprogramming myeloid cells to support anti-tumor immunity.
  • Personalized Medicine Approach: Personalized medicine is becoming a major trend in the myeloid cell targeting therapeutic market. By leveraging genetic profiling and immune profiling, researchers are able to identify specific subtypes of myeloid cells that influence disease progression, particularly in cancer and autoimmune disorders. Targeting these specific cell populations with tailored therapies is leading to improved clinical outcomes and fewer side effects. This trend is expected to continue as advances in genomics and immunology allow for better patient stratification, optimizing therapeutic efficacy and safety.
  • Combination Therapies: The combination of myeloid cell targeted therapies with other treatments such as chemotherapy, radiation therapy, and biologics is becoming a prominent approach. This trend capitalizes on the synergistic effects of combining immune modulation with conventional treatments to overcome resistance mechanisms. For instance, combining macrophage reprogramming agents with checkpoint inhibitors is showing promise in enhancing tumor responsiveness. This strategy aims to tackle the tumor microenvironment's complexity by addressing multiple facets of immune suppression, improving overall treatment efficacy and reducing relapse rates.
  • Expansion in Autoimmune Disease Treatment: While cancer has traditionally been the primary focus of myeloid cell targeting therapies, there is an increasing shift toward autoimmune diseases. Myeloid cells, particularly dendritic cells and macrophages, play a crucial role in the development of autoimmune conditions like rheumatoid arthritis and multiple sclerosis. Targeting these cells to restore immune tolerance is gaining traction as a novel therapeutic approach. This trend is expanding the market's scope, with myeloid-targeted drugs being developed for a broader range of inflammatory diseases beyond oncology.
  • Regulatory Advancements and Accelerated Approvals: Regulatory bodies in key regions, including the U.S., China, and the EU, are adopting more flexible and expedited approval pathways for myeloid cell targeting therapies. This trend is driven by the growing need for innovative treatments in oncology and chronic diseases. For example, the FDA's Breakthrough Therapy designation and China's conditional approval process are facilitating faster access to these therapeutics. Regulatory support for early-phase clinical trials and approval of novel immunotherapies is accelerating market growth, allowing myeloid-targeted drugs to reach patients more quickly.

These emerging trends in myeloid cell targeting therapeutics are revolutionizing the treatment landscape. By integrating with cancer immunotherapy, adopting personalized approaches, combining with other treatments, expanding into autoimmune diseases, and benefiting from regulatory advancements, the market is poised for significant growth. These trends are not only driving innovation but are also expanding the therapeutic scope, providing new avenues for treating a wide range of diseases.

Recent Developments in the Myeloid Cell Targeting Therapeutic Market

Recent advancements in myeloid cell targeted therapies have brought about notable progress, particularly in immunotherapy. Researchers are exploring new ways to manipulate myeloid cells, including macrophages, dendritic cells, and MDSCs, to treat cancer and autoimmune diseases. These developments represent an exciting shift in therapeutic strategies, with multiple advancements influencing drug discovery, clinical trials, and market growth. The following are key developments in the myeloid-targeting therapeutics market.

  • Breakthroughs in MDSC Modulation for Cancer Treatment: Targeting myeloid-derived suppressor cells (MDSCs) has emerged as a breakthrough in cancer immunotherapy. These cells contribute to tumor-induced immunosuppression, preventing effective anti-cancer immune responses. Recent developments have led to the discovery of novel drugs and immune modulators that can reprogram MDSCs, enhancing the body's immune response to tumors. Early-stage clinical trials are showing promising results, especially in combination with immune checkpoint inhibitors, positioning MDSC modulation as a critical component of next-generation cancer therapies.
  • Advances in Targeting Macrophage Polarization: Macrophages can have both pro-inflammatory and anti-inflammatory roles, and targeting macrophage polarization has shown therapeutic potential in cancer and chronic inflammatory diseases. Recent studies have focused on reprogramming macrophages from an immunosuppressive M2 phenotype to a tumoricidal M1 phenotype. Researchers are developing small molecules and biologic agents that can shift macrophage polarization, providing a new therapeutic approach. This strategy is advancing in clinical trials, with early results suggesting improvements in tumor regression and immune system activation.
  • New Clinical Trials in Autoimmune Diseases: The focus on myeloid cells is expanding beyond oncology into autoimmune diseases. Recent clinical trials have explored therapies that target dendritic cells and macrophages to modulate immune responses and restore tolerance. These therapies aim to treat conditions like rheumatoid arthritis, lupus, and multiple sclerosis, where immune dysregulation plays a key role. Clinical developments in this area are still in early stages, but they hold promise for improving patient outcomes in autoimmune disease management.
  • Collaboration Between Biotech Firms and Academia: There has been a surge in collaboration between biotech companies and academic institutions to advance research in myeloid-targeted therapies. These partnerships are essential for translating laboratory discoveries into clinical applications. Notable collaborations have accelerated the development of novel biomarkers for patient selection, improving the efficacy of therapies targeting myeloid cells. These collaborations are paving the way for the next generation of immunotherapies and expanding the therapeutic applications of myeloid-targeted treatments.
  • Increased Investment in Immuno-oncology Drugs: Increased investment from both private and public sectors is fueling innovation in the myeloid cell targeting therapeutic market. Immuno-oncology, particularly therapies that target the tumor microenvironment, has become a major focus for biotech companies. Significant funding has been directed toward research on macrophages, dendritic cells, and MDSCs to overcome immune resistance in tumors. This growing investment is accelerating the development and commercialization of new myeloid-targeted therapies, leading to a more competitive and dynamic market.

Recent developments in the myeloid cell targeting therapeutic market are positioning it as a rapidly advancing and highly dynamic field. From breakthroughs in MDSC modulation to new clinical trials for autoimmune diseases, these advancements are reshaping the therapeutic landscape. Increased investments, academic collaborations, and the expansion into autoimmune diseases and cancer are driving the growth of this market, which holds immense potential for revolutionizing the treatment of various diseases.

Strategic Growth Opportunities in the Myeloid Cell Targeting Therapeutic Market

The myeloid cell targeting therapeutic market presents significant growth opportunities across various applications, including oncology, autoimmune diseases, and chronic inflammatory conditions. These opportunities are fueled by advancements in immunology, regulatory changes, and growing investments in biotech. Understanding these growth areas can help companies and stakeholders capitalize on emerging market trends. Below are key applications driving strategic growth in the myeloid-targeted therapeutics space.

  • Cancer Immunotherapy: Cancer immunotherapy remains the largest application for myeloid cell targeted therapeutics. Targeting macrophages, MDSCs, and dendritic cells to modify the tumor microenvironment is showing promising potential in clinical trials. Combining myeloid-targeted therapies with existing treatments like checkpoint inhibitors and CAR-T therapies is expected to significantly enhance tumor response rates. This area is likely to see rapid growth as more companies develop drugs to modulate the immune system's ability to recognize and attack cancer cells.
  • Autoimmune Disease Treatment: There is a growing recognition of the role myeloid cells play in autoimmune diseases. Targeting dendritic cells and macrophages to restore immune tolerance presents a promising approach for treating conditions like rheumatoid arthritis, lupus, and multiple sclerosis. As the understanding of myeloid cell biology deepens, therapeutic strategies aimed at these cells are becoming a key opportunity for growth. This expanding application in autoimmune diseases is expected to become a significant driver for the market.
  • Chronic Inflammatory Disease Management: Chronic inflammatory diseases, such as asthma and inflammatory bowel disease (IBD), present a large unmet medical need. Myeloid cells, especially macrophages, play a central role in chronic inflammation. Targeting these cells to modulate inflammatory responses is a key growth opportunity. Novel myeloid-targeted therapies could offer more effective treatments with fewer side effects compared to traditional anti-inflammatory drugs. This segment is expected to grow as new therapeutics are developed for managing chronic inflammation.
  • Rare Disease Treatment: Targeting myeloid cells for rare diseases, such as certain types of genetic immunodeficiency's and lysosomal storage disorders, are an emerging growth area. These conditions often involve immune dysregulation, making myeloid cells an attractive therapeutic target. While the market for rare diseases is smaller, the potential for breakthroughs and orphan drug designations presents strategic opportunities for growth in this niche.
  • Next-Generation Therapeutics Development: The development of next-generation myeloid-targeted therapeutics, including gene editing tools like CRISPR and RNA-based therapies, presents a promising growth opportunity. These advanced technologies allow for highly precise targeting of myeloid cells, potentially offering curative treatments for various diseases. This area is still in early development stages but could revolutionize the treatment of myeloid-related disorders in the near future.

Strategic growth opportunities in the myeloid cell targeting therapeutic market are diverse and expanding across multiple applications. Oncology, autoimmune diseases, chronic inflammation, and rare diseases offer significant potential for market players. As research continues to unlock the therapeutic potential of myeloid cell modulation, these opportunities will drive the development of innovative therapies, reshaping the future of immunotherapy.

Myeloid Cell Targeting Therapeutic Market Driver and Challenges

The myeloid cell targeting therapeutic market is shaped by various drivers and challenges, ranging from technological innovations to regulatory hurdles. Understanding these factors is essential for stakeholders aiming to capitalize on the market's growth potential. The following section explores the key drivers and challenges that are influencing the market dynamics.

The factors responsible for driving the myeloid cell targeting therapeutic market include:

1. Technological Advancements in Immunotherapy: Recent technological innovations in immunotherapy, including the development of immune checkpoint inhibitors and CAR-T therapies, are driving the myeloid cell targeting therapeutic market. These advancements enable the targeting of myeloid cells to enhance immune responses against tumors and other diseases. The growing understanding of myeloid cell biology is opening up new therapeutic avenues, accelerating market growth.

2. Increasing Cancer Incidence and Unmet Medical Needs: The rising incidence of cancer globally is a major driver of the myeloid cell targeting therapeutic market. Cancer therapies that can manipulate the tumor microenvironment, including targeting myeloid cells, are in high demand. The limited effectiveness of conventional therapies and the need for more personalized treatments create a significant opportunity for myeloid-targeted therapies.

3. Growing Investment in Biotechnology: Increased investment in biotechnology, particularly in the immunotherapy and cell-based therapy sectors, is fueling the development of myeloid cell targeted therapeutics. With funding from both public and private sectors, research and development in this area are accelerating. These investments are supporting clinical trials, regulatory approvals, and commercialization efforts, further propelling market growth.

4. Favorable Regulatory Environment: The regulatory environment in key regions, including the U.S., China, and the EU, is evolving to support faster approvals for myeloid-targeted therapies. Agencies like the FDA and EMA are facilitating the development of novel immunotherapies through accelerated approval processes. This regulatory support is driving the market by reducing development timelines and improving access to innovative treatments.

5. Advancements in Personalized Medicine: The shift toward personalized medicine is a significant driver in the myeloid cell targeting therapeutic market. By leveraging genomic and immune profiling, companies can develop therapies tailored to individual patients. This trend is improving treatment outcomes and expanding the use of myeloid-targeted therapies in personalized cancer treatment and autoimmune disease management.

Challenges in the myeloid cell targeting therapeutic market are:

1. High Development Costs: The high costs associated with developing myeloid-targeted therapeutics pose a significant challenge. Research and clinical trials for immunotherapies are expensive, and the need for specialized manufacturing processes adds to the cost burden. These financial challenges could limit the accessibility of myeloid-targeted therapies, especially in low-income regions.

2. Regulatory Complexity: Despite regulatory advancements, navigating the complex regulatory pathways for new myeloid-targeted therapies remains challenging. Differences in approval processes across regions can delay market entry and increase development costs. Furthermore, the need for extensive clinical data to demonstrate safety and efficacy adds to the regulatory burden.

3. Limited Understanding of Myeloid Cell Biology: While progress has been made, there is still much to learn about the complex biology of myeloid cells. A deeper understanding is needed to effectively target these cells and predict how therapies will interact with the immune system. The lack of comprehensive knowledge may slow down the development of effective and precise therapies.

The myeloid cell targeting therapeutic market is driven by technological advancements, increasing cancer rates, growing biotechnology investments, and favorable regulatory environments. However, challenges such as high development costs, regulatory complexity, and limited understanding of myeloid cell biology could hinder growth. Addressing these issues will be crucial to fully unlocking the market's potential.

List of Myeloid Cell Targeting Therapeutic Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies myeloid cell targeting therapeutic companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the myeloid cell targeting therapeutic companies profiled in this report include-

  • ChemoCentryx
  • Daiichi Sankyo
  • Gilead Sciences
  • Janssen Biotech
  • Roche
  • Pfizer
  • GlaxoSmithKline
  • Macrophage Pharma
  • Enlivex
  • Immune-Onc Therapeutics

Myeloid Cell Targeting Therapeutic Market by Segment

The study includes a forecast for the global myeloid cell targeting therapeutic market by type, application, and region.

Myeloid Cell Targeting Therapeutic Market by Type [Value from 2019 to 2031]:

  • Intravenous Injection
  • Oral
  • Others

Myeloid Cell Targeting Therapeutic Market by Application [Value from 2019 to 2031]:

  • Oncological Disorders
  • Rare Disorders
  • Others

Myeloid Cell Targeting Therapeutic Market by Region [Value from 2019 to 2031]:

  • North America
  • Europe
  • Asia Pacific
  • The Rest of the World

Country Wise Outlook for the Myeloid Cell Targeting Therapeutic Market

The myeloid cell targeting therapeutic market, focused on targeting immune cells like macrophages, dendritic cells, and myeloid-derived suppressor cells (MDSCs), is witnessing significant advancements due to breakthroughs in immunotherapy. This sector is gaining attention as researchers explore ways to modulate myeloid cell activity for conditions like cancer, autoimmune diseases, and chronic inflammation. Major developments are underway in the United States, China, Germany, India, and Japan, where innovative therapeutic strategies and regulatory frameworks are accelerating. This progress is shaping the future of immunotherapy, with the potential to revolutionize treatment paradigms in oncology and immunology.

  • United States: The U.S. remains a global leader in myeloid cell targeted therapeutics, with substantial investments in research and development. The approval of several immunomodulatory drugs and clinical trials focusing on MDSC modulation are driving the market. Key players are exploring novel approaches like checkpoint inhibitors and CAR-T therapies aimed at enhancing immune system activation. The collaboration between biotechnology companies and academic institutions is fostering innovation, and regulatory agencies like the FDA are facilitating faster approval pathways for myeloid-targeting drugs. These advancements are promising to enhance the treatment landscape for cancer and chronic inflammatory diseases in the U.S.
  • China: China has seen rapid advancements in the myeloid cell targeting therapeutic market, with a growing focus on immunotherapy to treat cancer and autoimmune diseases. The Chinese government's support for biopharma R&D, along with favorable regulatory policies, has led to an increase in clinical trials investigating myeloid cell modulation. Notably, research on MDSCs as immune suppressors in tumors is gaining momentum. Chinese biotech companies are collaborating with international firms, boosting innovation and expanding the market for myeloid-targeted therapies. The government's "Made in China 2025" initiative is further accelerating the development of these therapies.
  • Germany: Germany is emerging as a key hub for myeloid cell targeted research in Europe, driven by strong public-private collaborations. The country's pharmaceutical sector is heavily investing in understanding how myeloid cells can be reprogrammed to fight cancer. Ongoing clinical trials are exploring therapies targeting macrophages and dendritic cells in various cancers, including breast cancer and glioblastoma. German universities and research institutes are leaders in the development of biomarkers and diagnostic tools to identify patients who could benefit from myeloid-targeted therapies. Regulatory bodies are facilitating faster approvals, contributing to the market's growth in Europe.
  • India: India's myeloid cell targeting therapeutic market is in the early stages, but it holds significant potential due to the country's growing biotech ecosystem and large patient population. Research and clinical trials focusing on immunomodulatory drugs are expanding, with particular interest in cancer and autoimmune diseases. Indian pharmaceutical companies are increasingly collaborating with international biotech firms, bringing affordable therapies to the local market. Government support for biopharma innovation is boosting the development of myeloid-targeted therapies. However, market growth faces challenges due to regulatory hurdles and a lack of robust healthcare infrastructure for advanced therapies.
  • Japan: Japan is an important player in the myeloid cell targeting therapeutic market, with the government prioritizing biopharma innovation. Japan's Ministry of Health, Labor, and Welfare (MHLW) has been supportive of early-phase clinical trials and regulatory approvals for immunotherapy targeting myeloid cells. Japanese pharmaceutical giants are heavily investing in cancer immunotherapy, particularly in targeting macrophages and MDSCs. The country's aging population and high incidence of cancers are driving demand for novel immunotherapies. Additionally, Japan's collaborative approach between industry and academia accelerates the development of cutting-edge therapeutics, positioning the country as a global leader in this space.

Features of the Global Myeloid Cell Targeting Therapeutic Market

  • Market Size Estimates: Myeloid cell targeting therapeutic market size estimation in terms of value ($B).
  • Trend and Forecast Analysis: Market trends (2019 to 2024) and forecast (2025 to 2031) by various segments and regions.
  • Segmentation Analysis: Myeloid cell targeting therapeutic market size by type, application, and region in terms of value ($B).
  • Regional Analysis: Myeloid cell targeting therapeutic market breakdown by North America, Europe, Asia Pacific, and Rest of the World.
  • Growth Opportunities: Analysis of growth opportunities in different type, application, and regions for the myeloid cell targeting therapeutic market.
  • Strategic Analysis: This includes M&A, new product development, and competitive landscape of the myeloid cell targeting therapeutic market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

This report answers following 11 key questions:

  • Q.1. What are some of the most promising, high-growth opportunities for the myeloid cell targeting therapeutic market by type (intravenous injection, oral, and others), application (oncological disorders, rare disorders, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
  • Q.2. Which segments will grow at a faster pace and why?
  • Q.3. Which region will grow at a faster pace and why?
  • Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
  • Q.5. What are the business risks and competitive threats in this market?
  • Q.6. What are the emerging trends in this market and the reasons behind them?
  • Q.7. What are some of the changing demands of customers in the market?
  • Q.8. What are the new developments in the market? Which companies are leading these developments?
  • Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
  • Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
  • Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Market Overview

  • 2.1 Background and Classifications
  • 2.2 Supply Chain

3. Market Trends & Forecast Analysis

  • 3.1 Macroeconomic Trends and Forecasts
  • 3.2 Industry Drivers and Challenges
  • 3.3 PESTLE Analysis
  • 3.4 Patent Analysis
  • 3.5 Regulatory Environment

4. Global Myeloid Cell Targeting Therapeutic Market by Type

  • 4.1 Overview
  • 4.2 Attractiveness Analysis by Type
  • 4.3 Intravenous Injection: Trends and Forecast (2019-2031)
  • 4.4 Oral: Trends and Forecast (2019-2031)
  • 4.5 Others: Trends and Forecast (2019-2031)

5. Global Myeloid Cell Targeting Therapeutic Market by Application

  • 5.1 Overview
  • 5.2 Attractiveness Analysis by Application
  • 5.3 Oncological Disorders: Trends and Forecast (2019-2031)
  • 5.4 Rare Disorders: Trends and Forecast (2019-2031)
  • 5.5 Others: Trends and Forecast (2019-2031)

6. Regional Analysis

  • 6.1 Overview
  • 6.2 Global Myeloid Cell Targeting Therapeutic Market by Region

7. North American Myeloid Cell Targeting Therapeutic Market

  • 7.1 Overview
  • 7.4 United States Myeloid Cell Targeting Therapeutic Market
  • 7.5 Mexican Myeloid Cell Targeting Therapeutic Market
  • 7.6 Canadian Myeloid Cell Targeting Therapeutic Market

8. European Myeloid Cell Targeting Therapeutic Market

  • 8.1 Overview
  • 8.4 German Myeloid Cell Targeting Therapeutic Market
  • 8.5 French Myeloid Cell Targeting Therapeutic Market
  • 8.6 Spanish Myeloid Cell Targeting Therapeutic Market
  • 8.7 Italian Myeloid Cell Targeting Therapeutic Market
  • 8.8 United Kingdom Myeloid Cell Targeting Therapeutic Market

9. APAC Myeloid Cell Targeting Therapeutic Market

  • 9.1 Overview
  • 9.4 Japanese Myeloid Cell Targeting Therapeutic Market
  • 9.5 Indian Myeloid Cell Targeting Therapeutic Market
  • 9.6 Chinese Myeloid Cell Targeting Therapeutic Market
  • 9.7 South Korean Myeloid Cell Targeting Therapeutic Market
  • 9.8 Indonesian Myeloid Cell Targeting Therapeutic Market

10. ROW Myeloid Cell Targeting Therapeutic Market

  • 10.1 Overview
  • 10.4 Middle Eastern Myeloid Cell Targeting Therapeutic Market
  • 10.5 South American Myeloid Cell Targeting Therapeutic Market
  • 10.6 African Myeloid Cell Targeting Therapeutic Market

11. Competitor Analysis

  • 11.1 Product Portfolio Analysis
  • 11.2 Operational Integration
  • 11.3 Porter's Five Forces Analysis
    • Competitive Rivalry
    • Bargaining Power of Buyers
    • Bargaining Power of Suppliers
    • Threat of Substitutes
    • Threat of New Entrants
  • 11.4 Market Share Analysis

12. Opportunities & Strategic Analysis

  • 12.1 Value Chain Analysis
  • 12.2 Growth Opportunity Analysis
    • 12.2.1 Growth Opportunities by Type
    • 12.2.2 Growth Opportunities by Application
  • 12.3 Emerging Trends in the Global Myeloid Cell Targeting Therapeutic Market
  • 12.4 Strategic Analysis
    • 12.4.1 New Product Development
    • 12.4.2 Certification and Licensing
    • 12.4.3 Mergers, Acquisitions, Agreements, Collaborations, and Joint Ventures

13. Company Profiles of the Leading Players Across the Value Chain

  • 13.1 Competitive Analysis
  • 13.2 ChemoCentryx
    • Company Overview
    • Myeloid Cell Targeting Therapeutic Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing
  • 13.3 Daiichi Sankyo
    • Company Overview
    • Myeloid Cell Targeting Therapeutic Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing
  • 13.4 Gilead Sciences
    • Company Overview
    • Myeloid Cell Targeting Therapeutic Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing
  • 13.5 Janssen Biotech
    • Company Overview
    • Myeloid Cell Targeting Therapeutic Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing
  • 13.6 Roche
    • Company Overview
    • Myeloid Cell Targeting Therapeutic Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing
  • 13.7 Pfizer
    • Company Overview
    • Myeloid Cell Targeting Therapeutic Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing
  • 13.8 GlaxoSmithKline
    • Company Overview
    • Myeloid Cell Targeting Therapeutic Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing
  • 13.9 Macrophage Pharma
    • Company Overview
    • Myeloid Cell Targeting Therapeutic Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing
  • 13.10 Enlivex
    • Company Overview
    • Myeloid Cell Targeting Therapeutic Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing
  • 13.11 Immune-Onc Therapeutics
    • Company Overview
    • Myeloid Cell Targeting Therapeutic Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing

14. Appendix

  • 14.1 List of Figures
  • 14.2 List of Tables
  • 14.3 Research Methodology
  • 14.4 Disclaimer
  • 14.5 Copyright
  • 14.6 Abbreviations and Technical Units
  • 14.7 About Us
  • 14.8 Contact Us

List of Figures

  • Figure 1.1: Trends and Forecast for the Global Myeloid Cell Targeting Therapeutic Market
  • Figure 2.1: Usage of Myeloid Cell Targeting Therapeutic Market
  • Figure 2.2: Classification of the Global Myeloid Cell Targeting Therapeutic Market
  • Figure 2.3: Supply Chain of the Global Myeloid Cell Targeting Therapeutic Market
  • Figure 2.4: Driver and Challenges of the Myeloid Cell Targeting Therapeutic Market
  • Figure 3.1: Trends of the Global GDP Growth Rate
  • Figure 3.2: Trends of the Global Population Growth Rate
  • Figure 3.3: Trends of the Global Inflation Rate
  • Figure 3.4: Trends of the Global Unemployment Rate
  • Figure 3.5: Trends of the Regional GDP Growth Rate
  • Figure 3.6: Trends of the Regional Population Growth Rate
  • Figure 3.7: Trends of the Regional Inflation Rate
  • Figure 3.8: Trends of the Regional Unemployment Rate
  • Figure 3.9: Trends of Regional Per Capita Income
  • Figure 3.10: Forecast for the Global GDP Growth Rate
  • Figure 3.11: Forecast for the Global Population Growth Rate
  • Figure 3.12: Forecast for the Global Inflation Rate
  • Figure 3.13: Forecast for the Global Unemployment Rate
  • Figure 3.14: Forecast for the Regional GDP Growth Rate
  • Figure 3.15: Forecast for the Regional Population Growth Rate
  • Figure 3.16: Forecast for the Regional Inflation Rate
  • Figure 3.17: Forecast for the Regional Unemployment Rate
  • Figure 3.18: Forecast for Regional Per Capita Income
  • Figure 4.1: Global Myeloid Cell Targeting Therapeutic Market by Type in 2019, 2024, and 2031
  • Figure 4.2: Trends of the Global Myeloid Cell Targeting Therapeutic Market ($B) by Type
  • Figure 4.3: Forecast for the Global Myeloid Cell Targeting Therapeutic Market ($B) by Type
  • Figure 4.4: Trends and Forecast for Intravenous Injection in the Global Myeloid Cell Targeting Therapeutic Market (2019-2031)
  • Figure 4.5: Trends and Forecast for Oral in the Global Myeloid Cell Targeting Therapeutic Market (2019-2031)
  • Figure 4.6: Trends and Forecast for Others in the Global Myeloid Cell Targeting Therapeutic Market (2019-2031)
  • Figure 5.1: Global Myeloid Cell Targeting Therapeutic Market by Application in 2019, 2024, and 2031
  • Figure 5.2: Trends of the Global Myeloid Cell Targeting Therapeutic Market ($B) by Application
  • Figure 5.3: Forecast for the Global Myeloid Cell Targeting Therapeutic Market ($B) by Application
  • Figure 5.4: Trends and Forecast for Oncological Disorders in the Global Myeloid Cell Targeting Therapeutic Market (2019-2031)
  • Figure 5.5: Trends and Forecast for Rare Disorders in the Global Myeloid Cell Targeting Therapeutic Market (2019-2031)
  • Figure 5.6: Trends and Forecast for Others in the Global Myeloid Cell Targeting Therapeutic Market (2019-2031)
  • Figure 6.1: Trends of the Global Myeloid Cell Targeting Therapeutic Market ($B) by Region (2019-2024)
  • Figure 6.2: Forecast for the Global Myeloid Cell Targeting Therapeutic Market ($B) by Region (2025-2031)
  • Figure 7.1: Trends and Forecast for the North American Myeloid Cell Targeting Therapeutic Market (2019-2031)
  • Figure 7.2: North American Myeloid Cell Targeting Therapeutic Market by Type in 2019, 2024, and 2031
  • Figure 7.3: Trends of the North American Myeloid Cell Targeting Therapeutic Market ($B) by Type (2019-2024)
  • Figure 7.4: Forecast for the North American Myeloid Cell Targeting Therapeutic Market ($B) by Type (2025-2031)
  • Figure 7.5: North American Myeloid Cell Targeting Therapeutic Market by Application in 2019, 2024, and 2031
  • Figure 7.6: Trends of the North American Myeloid Cell Targeting Therapeutic Market ($B) by Application (2019-2024)
  • Figure 7.7: Forecast for the North American Myeloid Cell Targeting Therapeutic Market ($B) by Application (2025-2031)
  • Figure 7.8: Trends and Forecast for the United States Myeloid Cell Targeting Therapeutic Market ($B) (2019-2031)
  • Figure 7.9: Trends and Forecast for the Mexican Myeloid Cell Targeting Therapeutic Market ($B) (2019-2031)
  • Figure 7.10: Trends and Forecast for the Canadian Myeloid Cell Targeting Therapeutic Market ($B) (2019-2031)
  • Figure 8.1: Trends and Forecast for the European Myeloid Cell Targeting Therapeutic Market (2019-2031)
  • Figure 8.2: European Myeloid Cell Targeting Therapeutic Market by Type in 2019, 2024, and 2031
  • Figure 8.3: Trends of the European Myeloid Cell Targeting Therapeutic Market ($B) by Type (2019-2024)
  • Figure 8.4: Forecast for the European Myeloid Cell Targeting Therapeutic Market ($B) by Type (2025-2031)
  • Figure 8.5: European Myeloid Cell Targeting Therapeutic Market by Application in 2019, 2024, and 2031
  • Figure 8.6: Trends of the European Myeloid Cell Targeting Therapeutic Market ($B) by Application (2019-2024)
  • Figure 8.7: Forecast for the European Myeloid Cell Targeting Therapeutic Market ($B) by Application (2025-2031)
  • Figure 8.8: Trends and Forecast for the German Myeloid Cell Targeting Therapeutic Market ($B) (2019-2031)
  • Figure 8.9: Trends and Forecast for the French Myeloid Cell Targeting Therapeutic Market ($B) (2019-2031)
  • Figure 8.10: Trends and Forecast for the Spanish Myeloid Cell Targeting Therapeutic Market ($B) (2019-2031)
  • Figure 8.11: Trends and Forecast for the Italian Myeloid Cell Targeting Therapeutic Market ($B) (2019-2031)
  • Figure 8.12: Trends and Forecast for the United Kingdom Myeloid Cell Targeting Therapeutic Market ($B) (2019-2031)
  • Figure 9.1: Trends and Forecast for the APAC Myeloid Cell Targeting Therapeutic Market (2019-2031)
  • Figure 9.2: APAC Myeloid Cell Targeting Therapeutic Market by Type in 2019, 2024, and 2031
  • Figure 9.3: Trends of the APAC Myeloid Cell Targeting Therapeutic Market ($B) by Type (2019-2024)
  • Figure 9.4: Forecast for the APAC Myeloid Cell Targeting Therapeutic Market ($B) by Type (2025-2031)
  • Figure 9.5: APAC Myeloid Cell Targeting Therapeutic Market by Application in 2019, 2024, and 2031
  • Figure 9.6: Trends of the APAC Myeloid Cell Targeting Therapeutic Market ($B) by Application (2019-2024)
  • Figure 9.7: Forecast for the APAC Myeloid Cell Targeting Therapeutic Market ($B) by Application (2025-2031)
  • Figure 9.8: Trends and Forecast for the Japanese Myeloid Cell Targeting Therapeutic Market ($B) (2019-2031)
  • Figure 9.9: Trends and Forecast for the Indian Myeloid Cell Targeting Therapeutic Market ($B) (2019-2031)
  • Figure 9.10: Trends and Forecast for the Chinese Myeloid Cell Targeting Therapeutic Market ($B) (2019-2031)
  • Figure 9.11: Trends and Forecast for the South Korean Myeloid Cell Targeting Therapeutic Market ($B) (2019-2031)
  • Figure 9.12: Trends and Forecast for the Indonesian Myeloid Cell Targeting Therapeutic Market ($B) (2019-2031)
  • Figure 10.1: Trends and Forecast for the ROW Myeloid Cell Targeting Therapeutic Market (2019-2031)
  • Figure 10.2: ROW Myeloid Cell Targeting Therapeutic Market by Type in 2019, 2024, and 2031
  • Figure 10.3: Trends of the ROW Myeloid Cell Targeting Therapeutic Market ($B) by Type (2019-2024)
  • Figure 10.4: Forecast for the ROW Myeloid Cell Targeting Therapeutic Market ($B) by Type (2025-2031)
  • Figure 10.5: ROW Myeloid Cell Targeting Therapeutic Market by Application in 2019, 2024, and 2031
  • Figure 10.6: Trends of the ROW Myeloid Cell Targeting Therapeutic Market ($B) by Application (2019-2024)
  • Figure 10.7: Forecast for the ROW Myeloid Cell Targeting Therapeutic Market ($B) by Application (2025-2031)
  • Figure 10.8: Trends and Forecast for the Middle Eastern Myeloid Cell Targeting Therapeutic Market ($B) (2019-2031)
  • Figure 10.9: Trends and Forecast for the South American Myeloid Cell Targeting Therapeutic Market ($B) (2019-2031)
  • Figure 10.10: Trends and Forecast for the African Myeloid Cell Targeting Therapeutic Market ($B) (2019-2031)
  • Figure 11.1: Porter's Five Forces Analysis of the Global Myeloid Cell Targeting Therapeutic Market
  • Figure 11.2: Market Share (%) of Top Players in the Global Myeloid Cell Targeting Therapeutic Market (2024)
  • Figure 12.1: Growth Opportunities for the Global Myeloid Cell Targeting Therapeutic Market by Type
  • Figure 12.2: Growth Opportunities for the Global Myeloid Cell Targeting Therapeutic Market by Application
  • Figure 12.3: Growth Opportunities for the Global Myeloid Cell Targeting Therapeutic Market by Region
  • Figure 12.4: Emerging Trends in the Global Myeloid Cell Targeting Therapeutic Market

List of Tables

  • Table 1.1: Growth Rate (%, 2023-2024) and CAGR (%, 2025-2031) of the Myeloid Cell Targeting Therapeutic Market by Type and Application
  • Table 1.2: Attractiveness Analysis for the Myeloid Cell Targeting Therapeutic Market by Region
  • Table 1.3: Global Myeloid Cell Targeting Therapeutic Market Parameters and Attributes
  • Table 3.1: Trends of the Global Myeloid Cell Targeting Therapeutic Market (2019-2024)
  • Table 3.2: Forecast for the Global Myeloid Cell Targeting Therapeutic Market (2025-2031)
  • Table 4.1: Attractiveness Analysis for the Global Myeloid Cell Targeting Therapeutic Market by Type
  • Table 4.2: Market Size and CAGR of Various Type in the Global Myeloid Cell Targeting Therapeutic Market (2019-2024)
  • Table 4.3: Market Size and CAGR of Various Type in the Global Myeloid Cell Targeting Therapeutic Market (2025-2031)
  • Table 4.4: Trends of Intravenous Injection in the Global Myeloid Cell Targeting Therapeutic Market (2019-2024)
  • Table 4.5: Forecast for Intravenous Injection in the Global Myeloid Cell Targeting Therapeutic Market (2025-2031)
  • Table 4.6: Trends of Oral in the Global Myeloid Cell Targeting Therapeutic Market (2019-2024)
  • Table 4.7: Forecast for Oral in the Global Myeloid Cell Targeting Therapeutic Market (2025-2031)
  • Table 4.8: Trends of Others in the Global Myeloid Cell Targeting Therapeutic Market (2019-2024)
  • Table 4.9: Forecast for Others in the Global Myeloid Cell Targeting Therapeutic Market (2025-2031)
  • Table 5.1: Attractiveness Analysis for the Global Myeloid Cell Targeting Therapeutic Market by Application
  • Table 5.2: Market Size and CAGR of Various Application in the Global Myeloid Cell Targeting Therapeutic Market (2019-2024)
  • Table 5.3: Market Size and CAGR of Various Application in the Global Myeloid Cell Targeting Therapeutic Market (2025-2031)
  • Table 5.4: Trends of Oncological Disorders in the Global Myeloid Cell Targeting Therapeutic Market (2019-2024)
  • Table 5.5: Forecast for Oncological Disorders in the Global Myeloid Cell Targeting Therapeutic Market (2025-2031)
  • Table 5.6: Trends of Rare Disorders in the Global Myeloid Cell Targeting Therapeutic Market (2019-2024)
  • Table 5.7: Forecast for Rare Disorders in the Global Myeloid Cell Targeting Therapeutic Market (2025-2031)
  • Table 5.8: Trends of Others in the Global Myeloid Cell Targeting Therapeutic Market (2019-2024)
  • Table 5.9: Forecast for Others in the Global Myeloid Cell Targeting Therapeutic Market (2025-2031)
  • Table 6.1: Market Size and CAGR of Various Regions in the Global Myeloid Cell Targeting Therapeutic Market (2019-2024)
  • Table 6.2: Market Size and CAGR of Various Regions in the Global Myeloid Cell Targeting Therapeutic Market (2025-2031)
  • Table 7.1: Trends of the North American Myeloid Cell Targeting Therapeutic Market (2019-2024)
  • Table 7.2: Forecast for the North American Myeloid Cell Targeting Therapeutic Market (2025-2031)
  • Table 7.3: Market Size and CAGR of Various Type in the North American Myeloid Cell Targeting Therapeutic Market (2019-2024)
  • Table 7.4: Market Size and CAGR of Various Type in the North American Myeloid Cell Targeting Therapeutic Market (2025-2031)
  • Table 7.5: Market Size and CAGR of Various Application in the North American Myeloid Cell Targeting Therapeutic Market (2019-2024)
  • Table 7.6: Market Size and CAGR of Various Application in the North American Myeloid Cell Targeting Therapeutic Market (2025-2031)
  • Table 7.7: Trends and Forecast for the United States Myeloid Cell Targeting Therapeutic Market (2019-2031)
  • Table 7.8: Trends and Forecast for the Mexican Myeloid Cell Targeting Therapeutic Market (2019-2031)
  • Table 7.9: Trends and Forecast for the Canadian Myeloid Cell Targeting Therapeutic Market (2019-2031)
  • Table 8.1: Trends of the European Myeloid Cell Targeting Therapeutic Market (2019-2024)
  • Table 8.2: Forecast for the European Myeloid Cell Targeting Therapeutic Market (2025-2031)
  • Table 8.3: Market Size and CAGR of Various Type in the European Myeloid Cell Targeting Therapeutic Market (2019-2024)
  • Table 8.4: Market Size and CAGR of Various Type in the European Myeloid Cell Targeting Therapeutic Market (2025-2031)
  • Table 8.5: Market Size and CAGR of Various Application in the European Myeloid Cell Targeting Therapeutic Market (2019-2024)
  • Table 8.6: Market Size and CAGR of Various Application in the European Myeloid Cell Targeting Therapeutic Market (2025-2031)
  • Table 8.7: Trends and Forecast for the German Myeloid Cell Targeting Therapeutic Market (2019-2031)
  • Table 8.8: Trends and Forecast for the French Myeloid Cell Targeting Therapeutic Market (2019-2031)
  • Table 8.9: Trends and Forecast for the Spanish Myeloid Cell Targeting Therapeutic Market (2019-2031)
  • Table 8.10: Trends and Forecast for the Italian Myeloid Cell Targeting Therapeutic Market (2019-2031)
  • Table 8.11: Trends and Forecast for the United Kingdom Myeloid Cell Targeting Therapeutic Market (2019-2031)
  • Table 9.1: Trends of the APAC Myeloid Cell Targeting Therapeutic Market (2019-2024)
  • Table 9.2: Forecast for the APAC Myeloid Cell Targeting Therapeutic Market (2025-2031)
  • Table 9.3: Market Size and CAGR of Various Type in the APAC Myeloid Cell Targeting Therapeutic Market (2019-2024)
  • Table 9.4: Market Size and CAGR of Various Type in the APAC Myeloid Cell Targeting Therapeutic Market (2025-2031)
  • Table 9.5: Market Size and CAGR of Various Application in the APAC Myeloid Cell Targeting Therapeutic Market (2019-2024)
  • Table 9.6: Market Size and CAGR of Various Application in the APAC Myeloid Cell Targeting Therapeutic Market (2025-2031)
  • Table 9.7: Trends and Forecast for the Japanese Myeloid Cell Targeting Therapeutic Market (2019-2031)
  • Table 9.8: Trends and Forecast for the Indian Myeloid Cell Targeting Therapeutic Market (2019-2031)
  • Table 9.9: Trends and Forecast for the Chinese Myeloid Cell Targeting Therapeutic Market (2019-2031)
  • Table 9.10: Trends and Forecast for the South Korean Myeloid Cell Targeting Therapeutic Market (2019-2031)
  • Table 9.11: Trends and Forecast for the Indonesian Myeloid Cell Targeting Therapeutic Market (2019-2031)
  • Table 10.1: Trends of the ROW Myeloid Cell Targeting Therapeutic Market (2019-2024)
  • Table 10.2: Forecast for the ROW Myeloid Cell Targeting Therapeutic Market (2025-2031)
  • Table 10.3: Market Size and CAGR of Various Type in the ROW Myeloid Cell Targeting Therapeutic Market (2019-2024)
  • Table 10.4: Market Size and CAGR of Various Type in the ROW Myeloid Cell Targeting Therapeutic Market (2025-2031)
  • Table 10.5: Market Size and CAGR of Various Application in the ROW Myeloid Cell Targeting Therapeutic Market (2019-2024)
  • Table 10.6: Market Size and CAGR of Various Application in the ROW Myeloid Cell Targeting Therapeutic Market (2025-2031)
  • Table 10.7: Trends and Forecast for the Middle Eastern Myeloid Cell Targeting Therapeutic Market (2019-2031)
  • Table 10.8: Trends and Forecast for the South American Myeloid Cell Targeting Therapeutic Market (2019-2031)
  • Table 10.9: Trends and Forecast for the African Myeloid Cell Targeting Therapeutic Market (2019-2031)
  • Table 11.1: Product Mapping of Myeloid Cell Targeting Therapeutic Suppliers Based on Segments
  • Table 11.2: Operational Integration of Myeloid Cell Targeting Therapeutic Manufacturers
  • Table 11.3: Rankings of Suppliers Based on Myeloid Cell Targeting Therapeutic Revenue
  • Table 12.1: New Product Launches by Major Myeloid Cell Targeting Therapeutic Producers (2019-2024)
  • Table 12.2: Certification Acquired by Major Competitor in the Global Myeloid Cell Targeting Therapeutic Market